demonstrate that the DPP4-i saxagliptin reduces beta-amyloid, tau accumulation (main culprits of neurodegeneration) and inflammatory markers and increases hippocampal GLP-1 and memory retention in mouse models of Alzheimer’s disease. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.